Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide

Overview of attention for article published in Journal for Immunotherapy of Cancer, October 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#48 of 3,470)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Altmetric has seen 29 news stories from 21 outlets.

Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF ), a clinical stage immuno-oncology company, today announced that the Society for…

GlobeNewswire 2017-11-13 Company Also Presents Poster Highlighting Preclinical Research on Combination Immunotherapies at SITC…

HALIFAX, Nova Scotia, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncol…

HALIFAX, Nova Scotia, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncol…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 25 additional news stories.